Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy

Abstract

The CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy has been widely proved effective on relapsed and refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL). Meanwhile, CAR-T therapy-related toxicities, including cytokine release syndrome (CRS) and neurological toxicities, are drawing researchers' attention. In addition, our research team notices that coagulopathy and even disseminated intravascular coagulation (DIC) are common problems during CAR-T therapy. In our phase 1/2 clinical trial (NCT02965092), 53 r/r B-ALL patients underwent leukapheresis on day − 11 and received lymphodepleting chemotherapy on day − 7 to day − 5. Finally, they received split infusions of anti-CD19 CAR-T cells on day 0 to day 2. Plasma concentrations of tissue factor (TF) and platelet endothelial cell adhesion molecular-1 (PECAM-1) were also measured to identify the mechanism of coagulation disorders. The overall 1-month remission rate of the 53 patients was 88.7%. During the treatment course, 19 patients experienced grade 3-4 CRS, 8 patients developed grade 2-3 neurological toxicities. Beyond that, 30 patients (30/53, 56.6%) suffered from coagulation disorders, and half of them should be diagnosed as DIC. Benefiting from replacement and anticoagulant therapy, 14 patients successfully got out of the conditions of DIC. Remarkably, the severity of coagulopathy was positively correlated with CRS grade. What is more, plasma TF and PECAM-1 levels indicated that vascular endothelial factors played key roles in the process of CRS-related coagulopathy. To conclude, coagulation disorders frequently happen during CAR-T therapy. TF and PECAM-1 are of great importance in the etiology and pathogenesis of coagulation problems. Early and proper interventions targeted at CRS-related coagulopathy contribute a lot to the control of side effects in CAR-T therapy.

T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis

“…Such high turn-over of CD25+ hyperactivated T-cells may contribute to immunothrombosis, which is immune-mediated acceleration of thrombosis and is another feature of severe COVID-19 (13). Intriguingly, the cancer immunotherapy chimeric antigen receptor T-cell (CAR-T) therapy uses gene-modified activated T-cells as effectors and can induce disseminated intravascular coagulation and immunothrombosis (58).…”

Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trial

“…In the first stage (NCT02965092), patients received anti‐CD19 CAR‐T therapy. The preparation of CAR‐T cells and the details of treatment were described previously …”

“…Flow cytometry was used to determine the transduction efficiency and the ratio of CAR‐T cells in peripheral blood and bone marrow after CAR‐T cell infusion. Detailed methods have been described . Once a patient received consolidative allo‐HSCT, the qPCR and flow cytometry was terminated.…”

“…In our preclinical research, we constructed a second‐generation CAR, in which the CD137 costimulatory signal was added to the CD3ζ signaling domain, which was described before (Figure S1A) . The CAR gene was inserted into the lentivirus vector, and the lentivirus was amplified in 293T cells.…”

Coagulopathy in COVID-19: Connecting the Dots Together

“…25 Around 70% of COVID-19 nonsurvivors and 0.6% of survivors meet the ISTH DIC diagnostic criteria during their hospital stay. 26 Most of them present a hypercoagulable state. However, it is unclear whether the pathophysiology of SIC, DIC, and CAC is the same and whether the terms can be used interchangeably.…”